Small-molecule Modulators Targeting SHP2 for Cancer Therapy

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• SHP2 (Src homology 2 domain-containing protein tyrosine phosphatase) is a critical regulator of intracellular signaling pathways implicated in cancer.
• Its involvement in oncogenesis makes SHP2 a highly attractive target for novel cancer therapeutics.

Purpose of the Study:

• To provide an overview of SHP2's structure, function, and regulation in cancer.
• To review and discuss current therapeutic strategies targeting SHP2, including their benefits and limitations.
• To explore future opportunities and challenges in SHP2-targeted cancer therapy.

Main Methods:

• Literature review and analysis of SHP2's role in cancer.
• Overview of SHP2 structure, function, and regulatory mechanisms.
• Discussion of therapeutic strategies: SHP2 protein tyrosine phosphatase (PTP) inhibitors, allosteric inhibitors, and Proteolysis-Targeting Chimeras (PROTACs).

Main Results:

• SHP2 regulates key cancer-associated signaling pathways, including RAS-ERK, PI3K-AKT, JAK-STAT, and PD-1/PD-L1, through conformational changes.
• SHP2 allosteric inhibitors demonstrate significant potency and broad applicability in preclinical and clinical cancer settings.
• Various therapeutic strategies targeting SHP2 show promise for diverse cancer types.

Conclusions:

• SHP2 represents a highly promising therapeutic target for cancer treatment.
• Targeting SHP2, particularly with allosteric inhibitors, offers a viable and effective alternative therapeutic approach for cancer patients.
• Continued research into SHP2-targeted therapies is warranted to overcome existing challenges and expand treatment options.